Organic compounds -- part of the class 532-570 series – Organic compounds – Unsubstituted hydrocarbyl chain between the ring and the -c-...
Reexamination Certificate
2005-05-24
2005-05-24
Baker, Maurie Garcia (Department: 1639)
Organic compounds -- part of the class 532-570 series
Organic compounds
Unsubstituted hydrocarbyl chain between the ring and the -c-...
C435S007100, C435S007200, C436S501000, C436S518000, C544S051000, C544S358000, C544S359000, C544S392000, C544S396000, C548S361100, C514S211040, C514S211050, C514S211060, C514S211070
Reexamination Certificate
active
06897305
ABSTRACT:
Novel multibinding compounds are disclosed. The compounds of this invention comprise 2-10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Ca++channel , thereby modulating the biological activities thereof.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4532248 (1985-07-01), Franckowiak et al.
patent: 4725597 (1988-02-01), Devlin et al.
patent: 4771057 (1988-09-01), Knaus et al.
patent: 4808605 (1989-02-01), Branca et al.
patent: 4902514 (1990-02-01), Barclay et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5120730 (1992-06-01), Pifferi et al.
patent: 5378698 (1995-01-01), Yamamori et al.
patent: 5462936 (1995-10-01), Yamamori et al.
patent: 5463564 (1995-10-01), Agrafiotis et al.
patent: 5571827 (1996-11-01), Barberich et al.
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 5686495 (1997-11-01), Goldin et al.
patent: 5723618 (1998-03-01), Leung-Toung et al.
patent: 5767131 (1998-06-01), Gluchowski et al.
patent: 5846839 (1998-12-01), Gallop et al.
patent: 5891643 (1999-04-01), Fesik et al.
patent: 6420560 (2002-07-01), Numerof et al.
patent: 1 179 342 (1984-12-01), None
patent: 2240325 (1998-06-01), None
patent: 0052300 (1982-05-01), None
patent: 0052300 (1982-05-01), None
patent: 0 122 488 (1984-10-01), None
patent: 0 266 549 (1988-05-01), None
patent: WO 9205802 (1992-04-01), None
patent: WO 9306121 (1993-04-01), None
patent: 9633972 (1996-10-01), None
patent: WO 9721445 (1997-01-01), None
patent: WO 9800439 (1998-01-01), None
patent: WO 9834948 (1998-08-01), None
Inoue et al. J. Med. Chem., 1991, vol. 34, No. 2, pp. 675-687.*
Nagao et al. Chem. Pharm. Bull., 1973, vol. 21, No. 1, pp. 92-97.*
Van Albada et al. Accession No.: 1995:776400; CAPLUS database on STN (Inorg. Chem. (1995), 34(19), pp. 4910-4917); Abstract only.*
Joslyn, A.F., et al. “Dimeric 1,4-dihydropryidines as calcium channel antagonists.”J. Med. Chem.31(8): 1489-1492 (1988).
Alker, D., et al. “Formation, Synthetic Utility and Structure Elucidation of a 2-Bromomethyl 1,4-Dihydropyridine.”Tetrahedron Letts.31: 1479-1482 (1990).
Arrowsmith, et al. “Long-Acting Dihydropyridine Calcium Antagonists. 1. 2-Alkoxymethyl Derivatives Incorporating Basic Substituents.”J. Med. Chem.29: 1696-1702 (1986).
Balboni, B., et al. “Calcium Antagonists: Vinylogues and bivalent ligands related to nifedipine.”Pharmazie.43: 318 (1988).
Bezprozvanny, I., et al. “Voltage-Dependent Blockade of Diverse Types of Voltage-Gated Ca2+Channels Expressed in Xenopus Oocytes by the Ca2+Channel Antagonist Mibefradil (Ro 40-5967).” Molec. Pharmacol. 48: 540-549 (1995).
Bossert, et al. “4-Aruldihydropyridines, a New Class of Highly Active Calcium Antagonists.”Angew. Chem. Int. Ed.20: 762-769 (1997).
Brittain, et al. “Relaxation of K+Contracted Rabbit Aortic Strips Implies Calcium Channel Blockade.”Physiologist, 28: 325 (1985).
Brenner, et al. “Encoded combinatorial chemistry.”Proc. Natl. Acad. Sci., USA, 89: 5181 (1992).
Cremers, et al. “Effects of the Novel T-Type Calcium Channel Antagonist Mibefradil on Human Myocardial Contractility in Comparison with Nifedipine and Verapamil.”J. Cardiovasc. Pharmacol.29: 692-696 (1997).
Cross, PE., et al. “Selective Class III Antiarrhythmic Agents. 1. Bis(arylalkyl)amines.”J. Med. Chem.33(4): 1151 (1989).
Denyer, et al. “HTS Approaches to Voltage-Gated Ion Channel Drug Discovery.” Drug Discovery today. 3(7):323-332 (1998).
Eltze, et al. “Stereoselective Inhibition of Thromboxane-Induced Coronary Vasoconstriction by 1,4-Dihydropyridine Calcium Channel Antagonists.”Chirality, 2: 233-240 (1990).
Gordeev, et al. “A General and Efficient Solid Phase Synthesis of Qynazoline-2,4-diones.” Tetrahedron Lett. 38(10): 1729-1732 (1997).
Gordeev, et al. “Approaches to Combinatorial synthesis of Heterocycles: A Solid Phase Synthesis of 1,4-Dihydropyridines.” J. Org. Chem. 61: 924-928 (1996).
Hess, et al. “Different modes of Ca channel gating behaviour favoured by dihydropyridine Ca agonists and antagonists.”Nature311: 538-544 (1984).
Hockerman, et al. “Molecular Determinants of Drug Binding and Action on L-Type Calcium Channels.”Annu. Rev. Pharmacol. Toxicol.37: 361-96 (1997).
Joslyn, et al. “Dimeric 1,4-Dihydropyridines as Calcium Channel Antagonists.”J. Med. Chem.31: 1489-1492 (1988).
Kenny, et al. “The Application of High-throughput Screening to Novel Lead Discovery.” Progress in Drug Research. Edited by Ernst Jucker. Herhauser Verlag: Basel, 1998, vol. 1, 246-269.
Kokubun, et al., “Studies on Ca Channels in Intact Cardiac Cells: Voltage-Dependent Effects and Cooperative Interactions of Dihydropyridine Enantiomers..”Molec. Pharmacol.30: 571-584 (1986).
Liang, R., et al. “Parallel synthesis and screening of a solid phase carbohydrate library.”Science, 274: 1520 (1996).
Osterrieder, W., et al. “In Vitro Phamacologic profile of Ro 40-5967, a Novel Ca2+Channel Blocker with Potent Vasodilator but Weak Inotropic Action.”Cardiovasc. Pharmacol.13: 754-9 (1989).
PD-029361. Current drug report.
Portoghese, P.S. “The Role of Concepts in Structure-Activity Relationship Studies of Opioid Ligands.”J. Med. Chem.35(11): 1927-1937 (1992).
Rampe, D., et al., “New synthetic ligands for L-type voltage-gated calcium channels.”Prog. Drug. Res.40: 191-238 (1993).
Rovnyak, G.C., et al. “Dihydropyrimidine Calcium Channel Blockers. 4. Basic 3-Substituted-4-aryl-1, 4-dihydropyrimidine-5-carboxylic Acid Ester. Potent Antihypertensive Agents.”J. Med. Chem.35: 3254-3263 (1992).
Shuker, S.B., et al. “Discovering High-Affinity Ligands for Proteins, SAR by NMR.” Science. 274: 1531-1534 (1996).
Tokuma, Y., et al. “Stereoselective pharmacokinetics of dihydropyridine calcium antagonists.”J. Chromatography A., 694: 181-193 (1995).
Yuen, P., et al. “Synthesis and SAR of sibustituted 1,2,3,4-tetrahydroisoquinoloines as N type Calcium channel blockers.”Bioorg and Med. Chem. Lett.8: 2415 (1998).
Zeng, et al. “Automated Analytical/Preparative High Performance Liquid Chromatography-Mass Spectrometry System for the Rapid Characterization and Purification of Compound Libraries.”J. Chrom. A.794:3-13 (1998).
Griffin John H.
Jenkins Thomas E.
Ji Yu-Hua
Natarajan Maya
Baker Maurie Garcia
Cohen Joyce G.
Hagenah Jeffrey A.
Saxon Roberta P.
Theravance Inc.
LandOfFree
Calcium channel drugs and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium channel drugs and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium channel drugs and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3427888